Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
Trial details
- Registry ID
- NCT06334133
- Phase
- Phase 3
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNCT06334133 | vTv Therapeutics | Phase 3 | Active not recruiting | 2027-04Estimated |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) SystemsNCT07616206 | vTv Therapeutics | Phase 2 | Not yet recruiting | 2027-06Estimated |
NCT07616206 · vTv Therapeutics
Apr 2027
Jun 2027
NCT06334133 · vTv Therapeutics
Sep 2026
Apr 2027
Recruiting
Active not recruiting